Grifols Alzheimer's drug AMBAR shows 61% reduction in disease progression
Grifols strengthened evidence for its AMBAR program with new real-world evidence data showing a 61% reduction in disease progression in patients with mild to moderate Alzheimer's disease compared with untreated patients. The AMBAR protocol is being implemented at hospitals in Spain and discussions are underway with additional centers for progressive adoption.
A. said new real-world evidence data strengthen the AMBAR program. The company said the AMBAR study showed a 61% reduction in disease progression in patients with mild to moderate Alzheimer’s disease compared with untreated patients. The AMBAR protocol has begun implementation at hospitals in Spain, and the company said it is also in discussions with other hospitals across Spain to explore a progressive adoption of the protocol at additional centers.
The findings expand evidence on the applicability of therapeutic plasma exchange with albumin replacement under routine clinical practice conditions. com; +48 58 769 66 00;))